Trastuzumab deruxtecan for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Mar 2025: Trial started, NCT06989112
  2. 25 May 2025: Trial registered, NCT06989112

The trials

NCT06989112: DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

State
Under way
Phase
Phase 3
People
600 planned
Started
27 Mar 2025
Primary completion
19 Jan 2029
Arms
Arm B: T-DXd + Pembrolizumab
Results
None posted
  1. 27 Mar 2025: Trial started
  2. 25 May 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Trastuzumab deruxtecan (DS-8201a), Trastuzumab deruxtecan (T-DXd, DS-8201a).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.